What do leaders of disease-specific advocacy organizations know about pharmacogenomics and biomarkers, anyway?

  title={What do leaders of disease-specific advocacy organizations know about pharmacogenomics and biomarkers, anyway?},
  author={Sharon F. Terry},
  journal={Personalized medicine},
  volume={6 2},
  • S. Terry
  • Published 13 March 2009
  • Biology
  • Personalized medicine
Disease Advocacy Organizations (DAOs) make meaningful contributions to the development of tests and therapeutics across the development pipeline, from cohort development to actual drug discovery. The process of developing biomarkers and validating them is fraught with a high failure rate and enormous expense. DAOs can harness new information technologies to increase effectiveness, including systems to dynamically consent individuals to participate in registries and trials. These new… 
2 Citations

Figures from this paper

A systematic literature review to identify ethical, legal, and social responsibilities of nonprofit organizations when funding clinical trials in pediatric cancer

A systematic review of the literature indexed in PubMed and Web of Science identified critical gaps in best practices for negotiating research partnerships, managing competing research priorities, and pursuing alternative financing models including venture philanthropy to guide NPOs in making trial funding decisions that align with stakeholder values and interests.

Care, Connect, Cure: Constructing Success for Health Consumer Organisations

In Australia, Health Consumer Organisations (HCOs), also known as Patient Support Groups, play an important role in supporting people facing a shared health condition. This research aims to identify



Validation of Analytic Methods for Biomarkers Used in Drug Development

This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.

Shaping the future of biomarker research in breast cancer to ensure clinical relevance

The consumers, clinicians, researchers, industry representatives and US regulators who served on the consensus panel developed a set of principles and recommendations to guide the field and ensure that biomarker research results in clinically important applications.

Science and society: Advocacy groups as research organizations: the PXE International example

PXE International, an advocacy organization for the disease pseudoxanthoma elasticum, provides an example of how research can be accelerated by advocacy groups that adopt methods that were pioneered by other advocacy organizations, and has integrated these along with new approaches into franchizable elements.

A model program to increase translation of rare disease genetic tests: collaboration, education, and test translation program

In 2006, The National Institutes of Health Office of Rare Diseases announced the Collaboration, Education, and Test Translation (CETT) Program, a pilot project to increase and improve the translation

Diabetes Research in Children Network: Availability of Protocol Data Sets

The DirecNet group has conducted nine protocols, resulting in 28 published manuscripts with an additional 2 under review and 5 in development, and has conducted several studies evaluating factors affecting hypoglycemia, including exercise and bedtime snack composition.

Emerging drug treatments for cystic fibrosis

  • P. Zeitlin
  • Medicine
    Expert opinion on emerging drugs
  • 2007
The current portfolio of investigational therapeutics for cystic fibrosis is explored here and placed in a context of therapeutic target and predicted clinical benefit.

Biological markers in Alzheimer's disease.

Alzheimer's disease (AD) is the most common type of dementia occurring in human population. The disorder is characterized clinically by memory loss and histopathologically by the presence of

Does the absence of ABCC6 (Multidrug Resistance Protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery?

The hypothesis implies that the symptoms of PXE can be prevented or mitigated by providing patients (intravenously) with a form of plasma vitamin K (precursor) that can be used by peripheral tissues.

Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms

Observations suggest the hypothesis that a consequence of loss‐of‐function mutations in the ABCC6 gene is the reduced vitamin K‐dependent γ‐glutamyl carboxylation of MGP, with subsequent connective tissue mineralisation.

Mutation detection in the ABCC6 gene and genotype–phenotype analysis in a large international case series affected by pseudoxanthoma elasticum

Genotype–phenotype analysis failed to reveal a significant correlation between the types of mutations identified or their predicted effect on the expression of the protein and the age of onset and severity of the disease, but the principal role of ABCC6 mutations is emphasised.